HERON THERAPS INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HERON THERAPS INC, and what generic alternatives to HERON THERAPS INC drugs are available?
HERON THERAPS INC has four approved drugs.
There are thirty-two US patents protecting HERON THERAPS INC drugs.
There are ninety-eight patent family members on HERON THERAPS INC drugs in twenty-one countries and seven supplementary protection certificates in four countries.
Summary for HERON THERAPS INC
| International Patents: | 98 |
| US Patents: | 32 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for HERON THERAPS INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | APONVIE | aprepitant | EMULSION;INTRAVENOUS | 216457-001 | Sep 16, 2022 | RX | Yes | Yes | 11,744,800 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-004 | May 12, 2021 | RX | Yes | Yes | 10,398,686 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-001 | May 12, 2021 | DISCN | Yes | No | 10,632,199 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HERON THERAPS INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | SUSTOL | granisetron | INJECTABLE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 9,913,910 | ⤷ Subscribe |
| Heron Theraps Inc | SUSTOL | granisetron | INJECTABLE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 10,357,570 | ⤷ Subscribe |
| Heron Theraps Inc | SUSTOL | granisetron | INJECTABLE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 8,715,710 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HERON THERAPS INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2022082776 | ⤷ Subscribe |
| South Korea | 102450730 | ⤷ Subscribe |
| Canada | 2579297 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for HERON THERAPS INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0748320 | SPC/GB08/021 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111 |
| 0734381 | SPC/GB04/011 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113 |
| 0734381 | PA2004002,C0734381 | Lithuania | ⤷ Subscribe | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
